0001593968-22-000515.txt : 20220222
0001593968-22-000515.hdr.sgml : 20220222
20220222160850
ACCESSION NUMBER: 0001593968-22-000515
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220218
FILED AS OF DATE: 20220222
DATE AS OF CHANGE: 20220222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Sean C.
CENTRAL INDEX KEY: 0001801993
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 22658120
MAIL ADDRESS:
STREET 1: C/O VERICEL CORPORATION
STREET 2: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
primary_01.xml
PRIMARY DOCUMENT
X0306
4
2022-02-18
0000887359
Vericel Corp
VCEL
0001801993
Flynn Sean C.
C/O VERICEL CORPORATION
64 SIDNEY STREET
CAMBRIDGE
MA
02139
false
true
false
false
VP, General Counsel
Common Stock
2022-02-19
4
M
false
1750
0
A
4314
D
Common Stock
2022-02-19
4
F
false
869
34.9
D
3445
D
Restricted Stock Unit
2022-02-19
4
M
false
1750
34.9
D
Common Stock
1750
5250
D
Stock Option (right to buy)
34.90
2022-02-18
4
A
false
51385
0
A
2032-02-18
Common Stock
51385
51385
D
Restricted Stock Unit
2022-02-18
4
A
false
9300
0
A
Common Stock
9300
9300
D
Stock Option (right to buy)
34.90
2022-02-18
4
A
false
2865
0
A
2032-02-18
Common Stock
2865
2865
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
No expiration date for this type of award.
These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.
/s/ Sean Flynn
2022-02-22